Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > ACADEMIA
ACADEMIA
- Opdivo Holds Promise as New Option for Malignant Pleural Mesothelioma: Pulmonary Specialist
September 21, 2018
- Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment
September 14, 2018
- 3-Year Cancer Survival Rate in Japan at 71%: NCC
September 13, 2018
- Japan Cancer Association to Release Statement on Health Spending at Sept. Meeting
August 24, 2018
- Only 30% of Patients Took Thyroid Tests before Receiving Dementia Meds: Survey
July 25, 2018
- Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
- Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors
July 11, 2018
- Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
July 5, 2018
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study
June 27, 2018
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
- Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
- Nephrology Society to Issue New CKD Guidelines; Recommends Less-Strict Blood Pressure Management Target
June 4, 2018
- AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist
May 28, 2018
- Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass
May 21, 2018
- Dupixent Used Generally as Adjunctive Therapy to Existing Treatments for Atopic Dermatitis: Dermatologist
May 10, 2018
- 55 Anticancer Meds Available Overseas Unapproved in Japan, 3 Meds Costing over 10 Million Yen Monthly: NCC
May 2, 2018
- New Guidelines Recommend LAMA as First-Line Bronchodilator for COPD: Respiratory Society
April 24, 2018
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…